89bio, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.89bio.com

Market Cap $808.03M
PE -3
Debt $35.54M
Cash $91.41M
EV $752.16M
FCF $NaN

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$288.96M
EBIT	-$284.66M
ROE	-76%
ROA	-62%
Equity	$378.10M
Growth Stability	1
PE	-2.8
PB	2.14
Price/Cash	0.11
Debt/Equity	0.09
Equity CAGR	39%
Earnings Growth YoY	329%
Earnings Growth QoQ	211%
Equity CAGR 5Y	45%

Equity CAGR 3Y	98%
Market Cap	$808.03M
Assets	$458.30M
Total Debt	$35.54M
Cash	$91.41M
Shares Outstanding	100.94M
EV	752.16M
Working Capital	417.08M
Current Ratio	11.66
Shares Growth 3y	63%
Equity Growth QoQ	-27%
Equity Growth YoY	-8%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

89bio Inc a United States-based clinical-stage biopharmaceutical company focused on the development of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin is a long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue. The fibroblast growth factor 21 (FGF21) is developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

SEC Filings

Direct access to 89bio, Inc. (ETNB) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does 89bio, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of 89bio, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

89bio, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for 89bio, Inc..

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-	-	-	-	-	-	-
ROA	-	-	-23%	-55%	-52%	-23%	-62%
ROE	-	-64%	-24%	-72%	-67%	-27%	-76%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-0.29	-0.24	-0.19	-
Debt over Equity	-	-	-	0.18	0.13	0.05	0.09
Growth Stability	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Good Debt/Equity ratio (0.09)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-	-	-	-	-	-
Earnings YoY growth	-	255%	-14%	82%	13%	39%	-
Equity YoY growth	-	-660%	126%	-38%	21%	253%	45%
FCF YoY growth	-	105%	81%	66%	6%	59%	-